Redefining Pharma Development – The View of a Tech CMC Company
By Mark Barrett, Group CEO, The Medicine Accelerator (APC & VLE Therapeutics)
2025 is set to be another momentous year for
The Medicine Accelerator.
In recent days, we secured planning permission for the €100 million expansion of our Medicine Accelerator Campus, ensuring this year will mark the next step on our journey as an Irish multinational. Our strategic plan, The Rise of The Medicine Accelerator, coincides with the campus launch and marks the maturity of key innovations within our future-focused CMC (Chemistry Manufacturing Controls) knowledge management platform, iAchieve®.
We are enabling our customers to achieve success at speed. This will be further enhanced by the expansion of our best-in-class CMC capabilities and the launch of predictive and generative AI-enabled CMC knowledge management within iAchieve®. These advancements act as a force multiplier for in-house scientific expertise, generating actionable insights to shape the future of medicine development.
This is a new winning formula for
medicine development and manufacture.
Foundations for Transforming Medicine Development - Tech CMC
Putting your living data to work in the service of your medicine rather than letting it stagnate in static reports that are trapped in the past.
Since our foundation in 2011, APC (and later, VLE Therapeutics) has been at the forefront of cutting-edge pharmaceutical development. We have pioneered advancements that redefine the possibilities for small- and large-molecule medicine development and manufacturing. Central to this is iAchieve®. Conceptualized, designed, and launched by our CMC experts for CMC experts, it is a groundbreaking platform that integrates real-time data and insights with cutting-edge AI technology tailored specifically to our customers' medicines.
2024 was a breakthrough year. We achieved staggering improvements in compressing CMC development timelines — in some cases, reducing time to manufacture by up to 40%. This progress lays the foundation to invent a new way to propel medicines to market and secure a unique market position as a “Tech CMC” company.
We have truly arrived at the point where deep tech can change how we catapult small and large molecule medicines to the market.
Specifically, we achieved a significant milestone in our industry-first journey. We have integrated +1,000,000 digital interactions in the development of our customers' medicines. This includes +350,000 forms of experiment design, +12,000 experiments, and +19,000 expert-led social CMC conversations.
These interactions enable greater speed, regulatory precision, and both qualitatively and quantitatively better outcomes
for our clients.
All digitally connected, forever. What was previously stored on paper, in notebooks, slides, ELNs, PLMs, emails, SharePoint, and more is now living and breathing as real-time medicine development histories on iAchieve. The foundation for accelerated development has been laid.
Customer-first. By structuring all inputs to be AI-readable, we have unlocked the capacity for generative and predictive AI that is specific to medicine. At the same time, by curating this data in client-specific containers, we provide holistic context for each step along the development journey. A multiyear and multimillion-euro journey has now matured, enabling us to continually deliver more value to our customers. This allows them to access and interrogate data that was previously trapped in backward-looking reports, rather than forward-looking possibilities.
Driving Enhanced Value through Partnership & Collaboration in 2025 and Beyond
A new vehicle for partnerships. The ‘partnership’ goal is valid, but the traditional approach to achieving it, in a way that can yield better results and value, may be outdated. It hasn’t moved with the times. We see the approach underpinned by iAchieve as the foundation and fuel for driving enhanced strategic partnership value. It is about delivering enhanced access, functionality, context, knowledge, and, importantly, ingenuity across the entire development and manufacturing pathway of medicines, ultimately adding real value.
I am convinced that this is the future of CMC
and the future of partnerships.
In 2025, with our digital foundations firmly in place, you will see us prioritize strengthening these relationships, ensuring that our partnerships yield maximum value in key areas, including: speed to patient, cost of manufacture, manufacturing precision, carbon footprint, and more.
A Bright Vision for the Future
As I look ahead, I am excited by the potential of what we can achieve together with our customers. Our team is developing, growing, and thriving. I love my connection with them and how it inspires my day-to-day activities. Our customers are addressing critical patient needs, touching the lives of millions, and, in turn, challenging us to do more.
2025 will see The Medicine Accelerator team, campus, our digital lens, and customer value proposition all maturing in parallel — a crossroads where the possibilities for new ways to accelerate medicines to patients can be realized.
Related Posts
Power Up Your Process Development Knowledge
Receive actionable process development insights and explore cutting edge process development news with great science delivered to your inbox every couple of months.